Equity by Design (EbD) in Clinical Research: The EbD Metrics Framework

Copyright: © 2022 MRCT Center. This work is licensed under a CC BY-NC-SA 4.0 license.
Acknowledgements:

This work would not have been possible without the exceptional advice, insights, and opinions of the Diversity, Equity and Inclusion (DEI) Roundtable. We express our sincerest thanks to: Sophia McLeod (Association of Clinical Research Organizations [ACRO]), Dr. Philip M. Alberti (Association of American Medical Colleges [AAMC]), Dr. James Powell (knowRx; Association of Multicultural Physicians), Dr. Camelia Thompson (Biotechnology Innovation Organization [BIO]), Yasmeen Long (Faster Cures, Milken Institute), RADM Richardae Araojo (U.S. Food and Drug Administration [FDA]), Dr. Milena Lolic (U.S. Food and Drug Administration [FDA]), Jennifer Dexter (National Health Council [NHC]), Silke Schoch (National Health Council [NHC]), Dr. Vanessa Marshall (National Institutes of Health [NIH]), and Maria Apostolaros (Pharmaceutical Research and Manufacturers of America [PhRMA]). They perceived the need for better DEI planning and goal setting, understanding of processes, accountability, and transparency among clinical research stakeholders, and advocated for the development of metrics that could provide guideposts for measurement and comparison of progress.

During the iterative process of refining the EbD Metrics Framework and developing operational approach examples, Dr. Jodi Yellin (Association of American Medical Colleges [AAMC]), Dr. Leslie Harden (Biotechnology Innovation Organization [BIO]), Rachael Fones (Diversity in Clinical Trials: IQVIA), Dr. Gnieisha Y. Dinwiddie (National Institutes of Health [NIH]), Dr. Monica Webb Hooper (National Institutes of Health [NIH]), Dr. George Mensah (National Institutes of Health [NIH]), and Dr. Lola Olufemi (National Institutes of Health [NIH]) also provided their invaluable thoughts and operational expertise through specific DEI Roundtable meetings, for which we also want to express our deep appreciation.

We are also grateful to colleagues at the Association for the Accreditation of Human Research Protection Programs (AAHRPP) and at Merck, to Trisha Hutzul (Johnson and Johnson Clinical Operations), Susan Knippenberg (Johnson and Johnson Clinical Operations), and Willow MacDonald (Johnson and Johnson Clinical Operations), and to Dr. Rodrigo Garcia (PPD, part of Thermo Fisher Scientific) and Dr. Susan McCune (PPD, part of Thermo Fisher Scientific) for taking the time to assess the design and utility of the EbD Metrics Framework and User Guide, for providing feedback on different themes, and when possible, for suggesting additional detail to be incorporated into the EbD Metrics Framework. Finally, this is a living document, and will benefit from the consideration, criticism, and suggestions of readers across the clinical research community. We look forward to your responses and thank-you for the shared dedication to improving clinical research and health outcomes for all.
Table of Contents
A. Commitment, leadership, and resources to support DEI in CR (“Commitment”) ................................................................. 1
B. Institutional and study metrics for DEI in CR, data collection, and analysis (“Data”) ................................................................. 2
C. 360-degree partnerships, communication, and engagement (“Engagement”) ............................................................................. 3
D. Educational and career opportunities to support DEI in CR (“Workforce”) .................................................................................. 4
E. Strategies for inclusion of diverse participant populations in CR (“Inclusion strategies”) .............................................................. 5
F. Review, accountability, and course adjustment (“Review”) ............................................................................................................. 6
G. Dissemination and expansion of work (“Dissemination”) .............................................................................................................. 7
List of Figures

Appendix 1: Operational Approach Example for A.1.2 "Public communication of commitment to DEI" ......................................................... 8
Appendix 2: Operational Approach Example for A.2.3 “Criteria for vendor selection and contracting to support DEI in CR” ......................... 9
Appendix 3: Operational Approach Example for B.1.3 “Defined purpose/s for the metrics, targets for success, and timeframes to assess the metrics” .......................................................................................................................... 10
Appendix 4: Operational Approach Example for C.2.2 “Communication platforms and materials that are physically accessible and usable for intended populations” .......................................................................................................................... 11
Appendix 5: Operational Approach Example for D.2.1 “Equitable and targeted opportunities for trainings in clinical research, grant applications, and professional development” ........................................................................................................................................ 12
Appendix 6: Operational Approach Example for E.1.3 “Eligibility criteria drafted for inclusivity” ................................................................. 13
Appendix 7: Operational Approach Example for F.1.1 “Cleaning and analysis of data and review of results” .................................................. 14
Appendix 8: Operational Approach Example for G.2.1 “Internal communication of results, analyses, and plans” ........................................ 15
Acronyms:

AI: Artificial Intelligence
CEO: Chief Executive Officer
CITI Program: Collaborative Institutional Training Initiative
CR: Clinical research
CRO: Contract Research Organization
DEI: Diversity, equity, and inclusion
EbD: Equity by Design
FDA: U.S. Food and Drug Administration
IRB: Institutional Review Board
MRCT Center: Multi-Regional Clinical Trials Center
TBD: To be determined
A. Commitment, leadership, and resources to support DEI in CR ("Commitment")

Description: Theme A focuses on leadership actions to make Diversity, Equity, and Inclusion (DEI) a priority within and across institutions/organizations. It encompasses processes such as creating a statement of commitment and clearly communicating that statement, and institutional support for commitment to DEI, both internally and externally. Theme A includes actions to set the stage for institutional accountability to DEI in Clinical Research (CR), including partnering with external advisors; designating and empowering institutional teams, committees, and positions to lead work in DEI; and committing to evaluation of institutional performance in DEI. Please note: the conception of metrics in A.2 relates to institutional (or study) performance and are reflected in the proposed quantitative and qualitative measures in this framework. However, the conception of metrics in A.3 relates to evaluating individual performance toward specific tasks involving DEI and, as they are specific to the individual, are beyond the scope of this document and are not enumerated here. Finally, Theme A also involves the generation or re-allocation of resources to support leadership, partner, and team commitment to DEI in CR.

<table>
<thead>
<tr>
<th>Quantitative</th>
<th>Qualitative</th>
</tr>
</thead>
<tbody>
<tr>
<td>QN.A % internal/external intended audience who are aware of the statement of commitment</td>
<td>A.1 Statement of commitment to DEI in clinical research by the President, Executive Leadership Team, and Board</td>
</tr>
<tr>
<td>QN.A % senior staff positions at the institution to coordinate/manage DEI (in full time equivalents)</td>
<td>A.1.1 Internal communication of commitment to DEI in CR</td>
</tr>
<tr>
<td>QN.A % funding committed for partnerships</td>
<td>A.1.2 Public communication of commitment to DEI (see Appendix 1)</td>
</tr>
<tr>
<td>QN.A Number external advisors that coordinate or regulate CR</td>
<td>A.2 Resource commitment to support DEI in CR across institution/organization</td>
</tr>
<tr>
<td>QN.A % research budget supporting studies focusing on underrepresented populations in CR and/or health equity</td>
<td>A.2.1 Assessments of the institution's financial, human, and physical resources to support DEI in CR</td>
</tr>
<tr>
<td>QN.A % research budget being spent with diverse clinical research vendors</td>
<td>A.2.2 Processes to generate/re-allocate financial, human, and physical resources to support DEI in CR</td>
</tr>
<tr>
<td></td>
<td>A.2.3 Criteria for vendor selection and contracting to support DEI in CR (see Appendix 2)</td>
</tr>
<tr>
<td></td>
<td>A.3 Executive Leadership Team and Board action on commitment for DEI in CR</td>
</tr>
<tr>
<td></td>
<td>A.3.1 Institutional/organizational partnerships with external advisors that coordinate or conduct CR</td>
</tr>
<tr>
<td></td>
<td>A.3.2 Processes for monitoring of institutional performance for DEI in CR</td>
</tr>
<tr>
<td></td>
<td>A.4 Dedicated teams, committees, positions and specific roles with identified institutional structure</td>
</tr>
<tr>
<td></td>
<td>A.4.1 Dedicated teams, committees, and positions for DEI (in CR and departments impacting CR)</td>
</tr>
<tr>
<td></td>
<td>A.4.2 Demarcated roles, tasks, and supervisory/reporting structures for teams, committees and positions for DEI</td>
</tr>
<tr>
<td></td>
<td>A.4.3 Processes for monitoring of team, committee, and individual position performance for DEI</td>
</tr>
</tbody>
</table>
B. Institutional and study metrics for DEI in CR, data collection, and analysis ("Data")

Description: Theme B centers on the processes for setting up metrics and data collection systems to evaluate institutional/organizational and/or study (i.e., clinical trial) performance on DEI in CR. This involves consideration of the purpose(s) for the metrics and the question(s) that are driving data collection and analysis, in addition to which variables, data sources, and forms of analysis would be needed to complete the analysis. Although some quantitative and qualitative metrics at the institutional level and study level may not always align, DEI success at the institutional and at the study level are interdependent. Therefore, the qualitative measures in Theme B attempt to be sufficiently broad to capture both institutional and study processes for developing metrics and data collection/analysis structures, but also specific enough so that the contextualization necessary for studies is not overlooked. Please note: Theme B does not yet include quantitative metrics. Qualitative metrics on analyses of data or review of results to plan for corrective action are covered in Theme F (Review).

B.1 Defined process to establish metrics for evaluating institutional or study performance on DEI in CR

B.1.1 Statement of purpose to capture, measure, and report DEI metrics in clinical trials from the President, Executive Leadership Team, and Board

B.1.2 Training, resources, and capacity to support the consideration, selection, and reporting of metrics

B.1.3 Defined purpose(s) for the metrics, targets for success, and timeframes to assess the metrics (see Appendix 3)

B.2 Identification of existing and/or needed data, variables, and data sources

B.2.1 Institutional and/or study question(s) defined in terms of the epidemiology of the condition(s) of concern and the population(s) of concern

B.2.2 Map of existing internal and external data sources that collect data from participants, patient records, electronic systems, and/or research records and the flow of data within the data infrastructure

B.2.3 Data source audit to identify data variables (e.g. race) and values (e.g. White, Black or African American, Asian) that can be utilized to meet data needs for the defined questions

B.3 Standardization of metrics and data collection and analysis practices

B.3.1 Data dictionary that aligns terminology and formatting for DEI metrics, variables, and values to be utilized, in compliance with the latest regulatory guidelines

B.3.2 Standardized data collection and reporting practices in place for departments or site(s)

B.3.3 Analytic methodologies to optimally answer the institutional or study question(s) with available data sources, variables, and values
C. 360-degree partnerships, communication, and engagement (“Engagement”)

**Description:** Theme C begins with recognizing that partnership with the community is critically important at the outset of clinical research and leads to the co-development of communication and engagement activities. Planning for respectful communication involves the actions to understand how internal and external audiences wish to be engaged. CR institutions/organizations can then develop necessary plans for physical, cultural, and linguistic accessibility (e.g., translation) of preferred modes of communication and participant-facing study materials. Theme C also encompasses processes to understand the lived experiences of individuals working and participating in clinical research and to build trust for initial and sustained engagement with community partners.

*Please note:* Partnerships with external advisors who coordinate or conduct clinical trials are covered under Theme A (Commitment). Mentorship and career development is included in Theme D (Workforce). In addition, while it is important to prepare for 360-degree Partnerships, Communication and Engagement through clinical research staff training in areas such as implicit bias and cultural competency, all clinical research training is considered under Theme D (Workforce). Review processes and accountability measures, including community review of partnership sustainability, are covered in Theme F (Review).

### Quantitative
- QN.C % CR Team/Executive Leadership Team members who are involved in community engagement efforts
- QN.C Number community partners (e.g. social welfare, community health, cultural, or religious organizations)
- QN.C Number community engagement activities in the last quarter; last 12 months; year-over-year
- QN.C % funding committed for community engagement
- QN.C Average length continuous institution-funded relationship with community site/s supporting underrepresented populations
- QN.C % CR team/executive team/board members that are from the intended population community

### Qualitative
- QN.C Developed and sustained partnerships with community sites, community organizations and community members
  - C.1.1 Defined process(es) for partnership with community sites, community groups, and their trusted members
  - C.1.2 Plan/s for community partner relationships to be supported and sustained

- C.2 Respectful and accessible communication platforms and materials
  - C.2.1 Terminology/imagery and communication that respect the preferences of intended audiences
  - C.2.2 Communication platforms and materials that are physically accessible and usable for intended populations (see Appendix 4)
  - C.2.3 Communication platforms and materials that are culturally and linguistically accessible and comprehensible to intended populations

- C.3 Opportunities for safe, respectful, empathetic, and open engagement
  - C.3.1 Internal: Lived experiences and related perspectives on clinical research are heard and understood
  - C.3.2 External: Lived experiences and related perspectives on clinical research are heard and understood
  - C.3.3 External: Connections fostered with community sites, trusted community members and potential trial participants
D. Educational and career opportunities to support DEI in CR (“Workforce”)

Description: Theme D focuses on actions to recruit and retain a diverse workforce that is representative of participant populations. It begins with recruitment, pipeline, and cohort programs for underrepresented clinical research staff, then moves to training and mentorships to support new hires. Finally, workforce retention also involves workplace environments, benefits, resources and support plans that enable all employees to remain physically and mentally healthy, performing at their best, and feeling valued. Please note: The term “clinical research staff” is not limited in scope to principal investigators and research coordinators, but also encompasses research nurses/assistants/monitors, patient navigators, pharmacists, medical writers, IRB chairs/members, scientists, technicians, regulatory professionals, etc. The term “equitable opportunities” implies equitable availability of, accessibility to, consideration for, and functioning of programs that will appropriately meet the training needs and learning styles of diverse clinical research staff. “Targeted opportunities” are those that specifically support underrepresented clinical research staff in surmounting structural barriers to participation.

Quantitative
- QN.D CR workforce representation/demographic & non-demographic data
- QN.D Leadership/management; funding/decision-making committees
- QN.D CR workforce hiring: applicants/interviews/offers/accepted offers
- QN.D CR workforce training: types/applications for/completion rates of trainings/certifications achieved
- QN.D CR workforce opportunities: promotions/support groups
- QN.D CR workforce satisfaction/retention

Qualitative
- Regularly collected variables
  - Age
  - Sex assigned at birth
  - Gender Identity
  - Race
  - Ethnicity
- Additional variables (examples)
  - Language
  - Person with a disability
  - Educational level
  - Veteran

D.1 Recruitment and pipeline programs for underrepresented CR staff
- D.1.1 Equitable and targeted opportunities to access institutionally supported pipeline/recruitment/cohort programs such as CR leadership development, internships/fellowships, or CR workforce training programs
- D.1.2 Vacancies for professional/volunteer positions in CR accessible to diverse audiences and applications fairly assessed

D.2 Clinical research training, development, mentorship programs for underrepresented CR staff
- D.2.1 Equitable and targeted opportunities for training in clinical research, grant applications, and professional development (see Appendix 5)
- D.2.2 Equitable and targeted opportunities for mentorship programs, training partnerships, or networking

D.3 Workplace environment supports the well-being and retention of employees from diverse backgrounds
- D.3.1 Required training for all employees on cultural humility, implicit bias, and accessibility by design
- D.3.2 Equitable and targeted benefits, flexible work policies, and opportunities to create/participate in support groups
- D.3.3 Retention strategies, individualized plans, and support available through human resources
E. Strategies for inclusion of diverse participant populations in CR (“Inclusion strategies”)

**Description:** Unlike the other themes in this framework that could be applicable to institutional/organizational, partnership, project, or study processes, Theme E is specific only to study processes. The measures under Theme E act in a way as a “backstop” to the measures in the other themes. That is because the measures in Theme E check that DEI recommendations have been included and specified throughout study plans, communication plans, and participant-facing materials. Please note: The qualitative measures in Theme E assume that implementation will follow in the manner specified in the study plans, and therefore separate measures are not listed for implementation. However, the quantitative measures in Theme E, and the qualitative measures in Theme F (Review) and Theme G (Dissemination), can be utilized to assess implementation of strategies for inclusion of diverse participant populations in the clinical research.

**Quantitative**

- QN.E Participants screened
- QN.E Eligible participants
- QN.E Participants who declined study enrollment
- QN.E Participants withdrew / dropped out
- QN.E Participants lost to follow-up
- QN.E Participants retained and completed study

**Regularly collected variables**

- Age
- Sex assigned at birth
- Gender Identity
- Race
- Ethnicity

**Additional variables (examples)**

- Language
- Person with a disability
- Educational level
- Income
- Insurance, etc.

**E.1 Study protocol drafted to be as inclusive as possible**

- E.1.1 Study question(s) identified based on relevance for intended populations
- E.1.2 Study designed to consider inclusion of intended populations (e.g., language, accessibility, frequency of visits, etc.)
- E.1.3 Eligibility criteria drafted for inclusivity (see Appendix 6)

**E.2 Planning for study feasibility, site selection**

- E.2.1 Feasibility assessments and selection of sites conducted with attention to DEI
- E.2.2 Supports to facilitate accessibility to clinical research by people of all abilities

**E.3 Planning inclusive processes for recruitment and retention of participants**

- E.3.1 Planning documents, including overall study and site-specific communication plans, communication platforms, and participant-facing materials are respectful and accessible
- E.3.2 Recruitment and retention plans that have been developed through community engagement and consider participants’ time, resources, and family/life circumstances
F. Review, accountability, and course adjustment (“Review”)

**Description:** Theme F involves actions to clean and analyze data (both quantitative and qualitative), and to review methodologies and results and of data analysis. Theme F enables stakeholders to begin drawing a picture of how well the institution/organization, team, or study progressed with their DEI efforts in CR and to evaluate what worked well and/or needs improvement. Collating and assessing all lessons learned will subsequently inform decision-making for course adjustment. This [institutional or study] course adjustment presents an opportunity to revise metrics and performance criteria, policies, tools, and to create mechanisms to hold institutions/staff responsible for outcomes. Please note: Theme F does not yet include quantitative metrics. In addition, as in other themes, careful consideration of all perspectives and forms of expertise necessary for these processes, and thus whom to involve, will be important. For example, the people ideally responsible for cleaning and analyzing data may not be the same as those who review results, generate lessons learned, and/or make decisions about corrective action. Also note that outputs from course adjustment in this theme loop back into Theme A (Commitment, specifically A.3.2), determination of metrics to be utilized in the future in Theme B (Data), and components of Theme C (Engagement), Theme D (Workforce), and Theme E (Inclusion strategies). Theme F also relates to Theme A (Commitment) in that F.3.3 assess if the commitment to develop metrics, embed them in review processes, and utilize them to hold institutions and staff accountable has been upheld. Theme F does not include dissemination of results, or advocacy for course adjustment or revised guidelines that are external to the institution or study (covered in Theme G - Dissemination).

### F.1 Cleaning and analysis of data and review of results
- **F.1.1** Cleaned and analyzed data for diversity, equity, and inclusion metrics in each theme (see Appendix 7)
- **F.1.2** Review of the methodologies and results of the data analyses

### F.2 Periodic review of goals and performance criteria
- **F.2.1** Collation of lessons learned; Assessment of any unintended consequences
- **F.2.2** Comparison of data analyses and lessons learned to goals and performance criteria

### F.3 Accountability and course adjustment
- **F.3.1** Accountability for DEI performance by institutions and staff
- **F.3.2** Revision of policies, standard operating procedures, investigator and IRB staff human participant education requirements, data forms, tools, and checklists
- **F.3.3** Revision of metrics and performance criteria
G. Dissemination and expansion of work (“Dissemination”)

Description: Theme G focuses upon the dissemination of results, lessons learned, and course adjustments generated in Theme F (Review) for the purposes of transparency and accountability. Theme G includes soliciting diverse views in communication preparations for return of results, grey- and peer-reviewed publications, planning documents, tools, and other materials for information dissemination. Regardless of the topic being communicated, principles of transparency such as timely reporting (to all intended audiences internal and/or external), use of plain language, clear descriptions of methodologies, and communication of favorable and unfavorable results should be upheld. Finally, Theme G encompasses advocacy for the work to be continuously evaluated, shared, and improved. While DEI metrics and goals for CR may be achieved, progress toward health equity and justice in CR are likely still needed. Theme G does not indicate an end of the road, but rather the opportunity for reflection and expansion of the work, for which stakeholders can revisit and (re)apply other themes and measures in this framework. Please note: Theme G does not yet include quantitative metrics.

G.1 Mechanisms to solicit diverse views in assessment, authorship, and advocacy of DEI efforts for CR
   G.1.1 Diverse clinical research staff involved in review and authorship
   G.1.2 Patients, caregiver/family, patient advocates, community members/organizations, community and institutional providers involved in review and authorship

G.2 Transparent and broad communication of results, analyses, and plans
   G.2.1 Internal communication of results, analyses, and plans (see Appendix 8)
   G.2.2 External communication of results, analyses and plans

G.3 Institutional advocacy for reducing disparities and improving health equity
   G.3.1 Institutional leaders and research teams active within institutional, local, national, or global networks/forums/conferences to share and/or promote practices, policies, and/or legislation
   G.3.2 Institutional leaders and research teams supporting others to access or generate forums within institutional, local, national, or global forums to promote DEI policies and/or legislation
Appendix 1: Operational Approach Example for A.1.2 "Public communication of commitment to DEI"

Quantitative Outcomes

| % internal/external intended audience who are aware of the statement of commitment |
| % funding committed for partnerships |
| % research budget supporting underrepresented populations in CR and/or health equity |
| Number partner external advisors that coordinate or regulate CR |
| % senior staff positions to coordinate/manage DEI (in full time equivalents) |

Qualitative Outcomes

<table>
<thead>
<tr>
<th>Strategic</th>
<th>Tactical</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1 Statement of commitment to DEI in clinical research by the President, Executive Leadership Team, and Board</td>
<td></td>
</tr>
<tr>
<td>A.1.2 Public communication of commitment to DEI</td>
<td></td>
</tr>
<tr>
<td>A.2 Resource commitment to support DEI in CR across institution/organization</td>
<td></td>
</tr>
<tr>
<td>A.3 Executive leadership team and Board action on commitment for DEI in CR</td>
<td></td>
</tr>
<tr>
<td>A.4 Dedicated teams, committees, positions and specific roles with identified institutional structure</td>
<td></td>
</tr>
</tbody>
</table>

Outputs

| What: Statement of commitment. The statement may include: |
| • DEI concepts |
| • Specific DEI goals |
| • Organizational values such as transparency |
| • A balance of institutional priorities (feasible/aspirational) |
| Where: [internal or external] |
| • Social media |
| • Organization webpage |
| • Organization newsletter |
| • Journal publication |

Activities/How

| Develop and communicate business, ethical, and/or scientific cases to bolster the statement of commitment |
| Evaluate best places to position/disseminate statement such that public, internal, and external partners are able to access. |
| [President, CEO, and Executive staff] Advocate for a public statement |

Inputs

| [By] Whom: |
| • President |
| • CEO |
| • Board |
| • Executive Committees |
| • Communication staff |

| [With] Whom: |
| • Principal Investigators |
| • Nurse Navigators |
| • Patient Advocates |
| • Intended Trial Participants |

| [With] Which [Micro/Project]: |
| • Budget |
| • Staffing time allocations |
| • Software/hardware/infrastructure |
### Appendix 2: Operational Approach Example for A.2.3 “Criteria for vendor selection and contracting to support DEI in CR”

#### Quantitative Outcomes

| % internal/external intended audience that is aware of the statement |
| % funding committed for partnerships |
| % research budget supporting underrepresented populations in CR and/or health equity |
| % research budget being spent with diverse clinical research suppliers |
| Number partner external advisors that coordinate or regulate CR |
| % senior staff positions to coordinate/manage DEI (in full time equivalents) |

#### Qualitative Outcomes

**Strategic**
- A.1. Statement of commitment to DEI in clinical research by the President, Executive Leadership Team, and Board

**Tactical**
- A.2. Resource commitment to support DEI in CR across institution/organization
- A.3 Executive Leadership Team and Board action on commitment for DEI in CR
- A.4 Dedicated teams, committees, positions and specific roles with identified institutional structure

#### Outputs

- What:
  - Criteria that specify a desired threshold for demographics of vendor personnel
  - Criteria that specify a vendor locale and/or service to a diverse community/s
  - Criteria that specify a threshold of vendor jobs created by diversity programs
  - Criteria that specify the expected vendor contribution to the goals of DEI in CR

- Institute penalties, such as claw backs of incentives, if contracts stipulate a grace period for criteria to be met and the criteria are not met

- Where:
  - Request for proposal
  - Contracts

#### Activities/How

- [Institution] Provide incentives such as matching funds

#### Inputs

- [By] Whom:
  - DEI teams
  - DEI committees
  - DEI roles
  - Procurement
  - Contracts
  - Finance Staff

- [With] Whom:
  - CROs
  - Data Analysis/AI Organizations
  - Equipment/Supply Vendors

- [With] Which
  - [Micro/Project]:
    - Budget
    - Staffing time allocations
    - Software/hardware/infrastructure
Appendix 3: Operational Approach Example for B.1.3 “Defined purpose/s for the metrics, targets for success, and timeframes to assess the metrics”

<table>
<thead>
<tr>
<th>Quantitative Outcomes</th>
<th>Qualitative Outcomes</th>
<th>Outputs</th>
<th>Activities/How</th>
<th>Inputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>Outcomes</td>
<td>Activities/How</td>
<td>B.1.3 Defined purpose/s for the metrics, targets for success, and timeframes to assess the metrics</td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>Outputs</td>
<td>Activities/How</td>
<td>B.1.1 Statement of purpose to capture, measure, and report DEI metrics in clinical trials from the President, Executive and Leadership Team, and Board</td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>Activities/How</td>
<td>Determine whether the metrics should be qualitative, quantitative, or both</td>
<td>[By] Whom: Sponsor and/or Principal Investigator, DEI teams/positions, Data Analysis Specialists</td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>[With] Which Micro/Project:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Define purpose/s for the metrics, targets for success, and timeframes to assess the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

Consider the potential timeframes to achieve the metrics.

Where:
- Internal reporting
- External reporting

Define the reporting process, for example ensure that the numerator and denominator are transparent.

With Whom:
- Nurse Navigator
- Patient Advocates
- Intended trial participants

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

By Whom:
- Sponsor and/or Principal Investigator
- DEI teams/positions
- Data Analysis Specialists

Determine whether the metrics should be qualitative, quantitative, or both.

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.

Leverage epidemiological and medical data related to prevalence of the condition.

[With] Which Micro/Project:
- Budget
- Staffing time allocations
- Software/hardware/infrastructure

Define the reporting process, for example ensure that the numerator and denominator are transparent.

Consider the potential timeframes to achieve the metrics.
Appendix 4: Operational Approach Example for C.2.2 “Communication platforms and materials that are physically accessible and usable for intended populations”

<table>
<thead>
<tr>
<th>Quantitative Outcomes</th>
<th>Qualitative Outcomes</th>
<th>Outputs</th>
<th>Activities/How</th>
<th>Inputs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strategic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% CR Team/Executive Leadership Team who are involved in community engagement</td>
<td>C.1 Developed and sustained partnerships with community sites, community organizations and community members</td>
<td>Incorporate universal design to support accessibility by people with disabilities</td>
<td>[By] Whom:</td>
<td></td>
</tr>
<tr>
<td>Number community partners e.g. social welfare, community health, cultural, or religious organizations</td>
<td>C.2 Respectful and accessible communication platforms and materials</td>
<td>Provide technology that clinical research staff, community members, and participants are expected to use, but can’t pay for (e.g. phones, internet connectivity)</td>
<td>[With] Whom:</td>
<td></td>
</tr>
<tr>
<td>Number community engagement activities in the last quarter or 12 months; year-over year</td>
<td>C.3 Opportunities for safe, respectful, empathetic, and open engagement</td>
<td>Test platforms for usability (e.g. checking all platform/helplines and platform pages are accessible) on all devices used (laptops, phones)</td>
<td>[With] Whom:</td>
<td></td>
</tr>
<tr>
<td>% funding committed to community engagement</td>
<td>C.2.3 Communication platforms and materials that are culturally and linguistically accessible and comprehensible to intended populations</td>
<td>Provide technical support for platform users (e.g., help lines; written instructions; training)</td>
<td>[With] Which</td>
<td></td>
</tr>
<tr>
<td>Average length continuous institution funded relationships with community site/s supporting underserved populations</td>
<td></td>
<td></td>
<td>Micro/Project:</td>
<td></td>
</tr>
<tr>
<td>% Board members that are from the intended population community</td>
<td></td>
<td></td>
<td>Budget</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Staffing time allocations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Software/hardware/infrastructure</td>
<td></td>
</tr>
</tbody>
</table>
Appendix 5: Operational Approach Example for D.2.1 “Equitable and targeted opportunities for trainings in clinical research, grant applications, and professional development”

**Quantitative Outcomes**
- CR workforce representation/demographic & non-demographic
- Leadership positions, funding/decision making committees, & management
- CR workforce hiring: applicants/interviews/offers/accepted offers
- CR workforce training: types, applications for/completion rates of trainings, certifications
- CR workforce opportunities: promotions/support groups
- CR workforce satisfaction/retention

**Qualitative Outcomes**

**Strategic**
- D.1 Recruitment and pipeline programs for underrepresented CR staff

**Tactical**
- D.2.1 Equitable and targeted opportunities for trainings in clinical research, grant applications, and professional development
  - What: Training in design and conduct of clinical trials
  - Data management training
  - Training in Writing a good research proposal
  - Boilerplates to improve access to applying, conducting, and executing research grants
  - Implicit bias training
  - Cultural humility training
  - DEI training
- D.2.2 Equitable and targeted opportunities for mentorship programs, training partnerships, or networking
- D.3 Workplace environment supports the well-being and retention of employees from diverse backgrounds

**Outputs**
- Define staff continuing education paths and skill/learning objective profiles
- Allocate [equitable] time for learning
- Reimburse tuition if applicable
- Assess the DEI training and engagements that clinical research staff, community members, and patient advocates feel have been the most helpful
- Document the opportunities presented and those pursued

**Activities/How**
- By Whom: Human Resources, CITI Program, Training consultants/partners
- With Whom: Institutional Leadership, IRBs, Principal Investigators, Study Coordinators, Nurse Navigators, Additional employees of organizations that work in CR or Clinical Researchers
- With Which Micro/Project: Budget, Staffing time allocations, Software/hardware/infrastructure

**Inputs**
Appendix 6: Operational Approach Example for E.1.3 “Eligibility criteria drafted for inclusivity”

<table>
<thead>
<tr>
<th>Quantitative Outcomes</th>
<th>Qualitative Outcomes</th>
<th>Outputs</th>
<th>Activities/How</th>
<th>Inputs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants</strong></td>
<td><strong>Strategic</strong></td>
<td><strong>Tactical</strong></td>
<td><strong>What:</strong></td>
<td><strong>Consider demographic and non-demographic variables within the intended participant population</strong></td>
</tr>
<tr>
<td>screened</td>
<td>E.1 Study Protocol drafted to be as inclusive as possible</td>
<td>E.1.1 Study question/s identified based on relevance for intended populations</td>
<td>Inclusivity</td>
<td><strong>Limiting exclusion only to when scientifically or ethically justified</strong></td>
</tr>
<tr>
<td>Eligible participants</td>
<td>E.2 Planning for feasibility, site selection</td>
<td>E.1.2 Study designed to consider inclusion of intended populations (e.g. language, accessibility, frequency of visits, etc.)</td>
<td></td>
<td><strong>Use precise wording so that terms so that broad groups are not excluded</strong></td>
</tr>
<tr>
<td>Participants who declined study enrollment</td>
<td>Participants retained and completed study</td>
<td>Participants withdrew/dropped out</td>
<td></td>
<td><strong>Documenting scientific or ethical justification for exclusion, when necessary</strong></td>
</tr>
<tr>
<td>Participants lost to follow-up</td>
<td></td>
<td></td>
<td><strong>List supports (e.g. wheelchairs, sign language, supported decision-making) provided to facilitate inclusion; or reason why support can’t be provided</strong></td>
<td></td>
</tr>
</tbody>
</table>

**[By] Whom:**
- Sponsors
- Principal investigators
- DEI teams/positions
- CROs
- Sites

**[With] Whom:**
- Study Coordinators
- Nurse Navigators
- Community organizations
- Cultural Ambassador
- Intended trial participants

**[With] Which [Micro/Project]:**
- Budget
- Staffing time allocations
- Software/hardware/infrastructure
### Quantitative Outcomes

<table>
<thead>
<tr>
<th>Strategic</th>
<th>Tactical</th>
</tr>
</thead>
<tbody>
<tr>
<td>F.1 Cleaning and analysis of data and review of results</td>
<td>F.1.1 Cleaned and analyzed data for diversity, equity, and inclusion metrics in each theme</td>
</tr>
<tr>
<td>F.2 Periodic review of goals and performance criteria</td>
<td>F.1.2 Review of the methodologies and results of the data analyses</td>
</tr>
<tr>
<td>F.3 Accountability and course adjustment</td>
<td></td>
</tr>
</tbody>
</table>

### Qualitative Outcomes

<table>
<thead>
<tr>
<th>Strategic</th>
<th>Tactical</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Outputs

**What:**
- Qualitative and quantitative data on institutional performance - Qualitative and quantitative data on DEI team/position performance
- Qualitative and quantitative data on study performance in DEI
- Qualitative and quantitative data relevant to specific study questions

**Where:**
- Completed data collection forms
- Institutional databases
- Site level databases
- Electronic health records.

### Activities/How

**Plan for the frequency of data review**
- Assess experience and capacity of people that are collating, cleaning, and analyzing data
- Develop criteria for assessing the quality and comprehensiveness of the datasets, statistical models, and significance thresholds used to determine if/what conclusions can be drawn
- Verify that safeguards (developed under Theme B) have been upheld with respect to whether AI has been assessing the appropriate data/measures

### Inputs

**[By] Whom:**
- Data cleaning and analysis specialists
- Principal investigators
- DEI teams/positions
- Sites

**[With] Whom:**
- Institutional Leadership

**[With] Which Micro/Project:**
- Budget
- Staffing time allocations
- Software/ hardware/ infrastructure
### Appendix 8: Operational Approach Example for G.2.1 “Internal communication of results, analyses, and plans”

<table>
<thead>
<tr>
<th>Quantitative Outcomes</th>
<th>Qualitative Outcomes</th>
<th>Outputs</th>
<th>Activities/How</th>
<th>Inputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>G.2.1 Internal communication of results, analyses, and plans</td>
<td>Use plain language and health literacy principles</td>
<td>[By] Whom: Institutional leadership, Principal investigators</td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>G.2.2 External communication of results, analyses and plans</td>
<td>Use respectful forms of address and terminology</td>
<td>[With] Whom: Communication teams, DEI teams/positions</td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>G.3 Institutional advocacy for reducing disparities and improving health equity</td>
<td>Use universal design to make communication accessible for people with disabilities</td>
<td>[With] Which [Micro/Project]: Budget, Staffing time allocations, Software/hardware/infrastructure</td>
</tr>
</tbody>
</table>

**Strategic**
- G.1 Mechanisms to solicit diverse views in assessment, authorship, and advocacy of DEI efforts for CR
- G.2 Transparent and broad communication of results, analyses, and plans
- G.3 Institutional advocacy for reducing disparities and improving health equity

**Tactical**
- G.2.1 Internal communication of results, analyses, and plans
- G.2.2 External communication of results, analyses and plans

**Outputs**
- What:
  - Institutional performance reviews/report cards
  - Departmental performance reviews/report cards
  - Trial results
  - Updated strategies, goals and commitments
  - Lessons learned and innovations
- Where:
  - Email
  - Website/Employee portal
  - Internal newsletter
  - Brown bags to discuss results

**Activities/How**
- Consider communication timing, so that some audiences do not receive needed information after others
- Translate communication where appropriate
- Consider which DEI metrics to communicate, and the level of granularity for the results